Company intelligence / Profile preview

Oncolix, Inc.

Houston, Texas, United States

Ownership: Private
Development stage: Other

Overview

Oncolix’s lead program Prolanta™ received FDA Orphan Drug status for ovarian cancer and demonstrated preclinical efficacy via induced autophagy and synergy with chemotherapy. As of the last public update, it was in an ongoing Phase I human clinical trial for ovarian cancer patients.

Therapeutic areas: Oncology
Modalities: Biological drug/protein therapeutic (Prolanta™)
Industry: Biotech

Drug pipeline

1 asset

Prolanta

Partnerships

Initial collaboration with The University Texas MD Anderson Cancer Center for preclinical research on Prolanta™ efficacy and mechanism.

Beyond the preview

Go deeper on Oncolix, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncolix, Inc..